Biomarkers of Extracellular-Vesicle Cargo Changes During Tissue Injury and Repair

Abstract

Extracellular vesicles (EVs) are critical mediators of intercellular communication, carrying diverse molecular cargo that reflects the physiological or pathological state of their cells of origin. In recent years, research has elucidated the dynamic alterations in EV cargo composition during tissue injury and subsequent repair, revealing their utility as sensitive biomarkers. This review synthesizes current evidence on EV-based biomarkers, including their molecular profiles, mechanistic roles in injury response, and potential clinical applications in diagnosis, prognosis, and therapeutic monitoring. Emphasis is placed on EV cargo changes in acute and chronic tissue damage, their pathophysiological underpinnings, risk stratification, and integration into modern clinical management and guidelines.

Introduction

Extracellular vesicles, comprising exosomes, microvesicles, and apoptotic bodies, are membrane-bound particles released by nearly all cell types under physiological and pathological conditions. These vesicles encapsulate proteins, lipids, nucleic acids, and metabolites, serving as vehicles for cell-to-cell signaling. During tissue injury and repair, the cargo composition of EVs undergoes marked changes, offering a window into the ongoing molecular processes. As such, EV-derived biomarkers are increasingly recognized for their potential in non-invasive diagnosis, risk assessment, and therapeutic guidance in a variety of tissue injury contexts, including cardiovascular, renal, hepatic, pulmonary, and musculoskeletal systems. Understanding the dynamic landscape of EV cargo alterations is essential for clinicians aiming to leverage these biomarkers to improve patient outcomes.

Epidemiology / Disease Burden

Tissue injury whether traumatic, ischemic, inflammatory, or degenerative remains a leading cause of morbidity and mortality worldwide. Cardiovascular diseases, acute kidney injury, liver failure, and chronic inflammatory conditions collectively contribute to a significant global health burden. Advances in early detection and monitoring tools are critically needed to reduce adverse outcomes. Epidemiological studies have documented elevated levels of circulating EVs in diverse patient populations experiencing tissue injury, correlating with disease severity and prognosis. The burden of disease underscores the clinical necessity for sensitive and specific biomarkers, making the study of EV cargo particularly relevant for contemporary medical practice.

Pathophysiology

Upon tissue insult, stressed or damaged cells rapidly alter the composition and quantity of released EVs. Mechanistically, cellular stress activates pathways such as p53, NF-κB, and oxidative stress responses, which in turn modulate the cargo of EVs. Proteomic and transcriptomic analyses have revealed enrichment of inflammatory cytokines, damage-associated molecular patterns (DAMPs), microRNAs (miRNAs), and mitochondrial DNA in EVs derived from injured tissues. These cargoes not only serve as biomarkers but also actively participate in propagating injury or promoting repair by influencing recipient cell phenotypes. For example, EVs from hypoxic cardiomyocytes carry miR-21, which modulates fibroblast activation and fibrosis, while those from injured neurons contain neurotrophic factors that support regeneration. The complexity of EV-mediated signaling underscores their dual role in both damage propagation and tissue recovery.

Risk Factors

Several patient-specific and environmental factors influence the profile and diagnostic performance of EV biomarkers. Age, comorbidities (such as diabetes, hypertension, and chronic inflammatory diseases), genetic predispositions, medication use, and lifestyle factors can all modulate EV release and cargo. Additionally, the nature, severity, and chronicity of tissue injury (acute vs. chronic, infectious vs. non-infectious) affect the molecular signature of circulating EVs. Understanding these risk modifiers is crucial for accurate interpretation of EV biomarker data and for personalizing risk stratification strategies in clinical practice.

Clinical Features

Clinically, tissue injury presents with organ-specific symptoms and laboratory abnormalities. However, traditional markers often lack sensitivity or specificity in the early detection and monitoring of injury. EV-based biomarkers have shown promise in bridging this gap. For example, in myocardial infarction, EVs enriched with cardiac-specific troponins, miR-1, and miR-208 rise rapidly post-injury, preceding conventional biomarkers. In acute kidney injury, tubular cell-derived EVs carrying neutrophil gelatinase-associated lipocalin (NGAL) or kidney injury molecule-1 (KIM-1) are detectable in urine before creatinine elevation. Similarly, in liver injury, hepatocyte-derived EVs containing miR-122 or albumin serve as early indicators of cellular damage. These clinical features highlight the added diagnostic value of EV biomarkers across organ systems.

Diagnosis

The diagnostic workflow for tissue injury is evolving to incorporate EV-based assays. Isolation techniques, such as ultracentrifugation, size-exclusion chromatography, and immunoaffinity capture, enable the enrichment of organ-specific EVs from blood, urine, or other body fluids. Molecular profiling via next-generation sequencing, mass spectrometry, and multiplex immunoassays facilitates the detection of diagnostic cargoes. Several studies have validated EV-derived miRNAs, proteins, and lipid signatures as diagnostic tools in myocardial infarction, stroke, acute kidney injury, and liver failure. Compared to traditional biomarkers, EV cargo offers improved sensitivity, specificity, and early detection capability, which is particularly beneficial in subclinical or rapidly evolving injury states.

Treatment & Management

While EV biomarkers primarily serve diagnostic and prognostic purposes, emerging evidence suggests their utility in guiding therapeutic decisions and monitoring response to interventions. Serial measurement of EV cargo can track injury progression, assess therapeutic efficacy, and detect complications such as secondary organ dysfunction. For instance, reduction in inflammatory or injury-associated EV cargoes following reperfusion therapy in acute myocardial infarction correlates with improved outcomes. In chronic diseases, longitudinal EV profiling may inform personalized treatment adjustments. Moreover, the therapeutic potential of engineered EVs loaded with anti-inflammatory or regenerative agents is under active investigation, opening new avenues for precision medicine.

Recent Advances / Emerging Therapies

Recent years have witnessed significant advances in EV research and translational application. High-throughput omics technologies have enabled the identification of novel EV cargo molecules with biomarker potential. Machine learning algorithms facilitate the interpretation of complex EV data, enhancing diagnostic accuracy. Therapeutically, preclinical studies have demonstrated the safety and efficacy of mesenchymal stem cell-derived EVs in models of myocardial, renal, and hepatic injury, with early-phase clinical trials underway. Efforts to standardize EV isolation, characterization, and reporting are improving the reproducibility and clinical utility of EV-based assays. The integration of EV biomarkers into multi-modal diagnostic panels, alongside imaging and conventional biomarkers, is a promising approach to comprehensive patient assessment.

Guideline Recommendations

While formal guideline incorporation of EV-based biomarkers is still in early stages, several expert consensus statements and position papers advocate for their research use and potential clinical translation. The International Society for Extracellular Vesicles (ISEV) and related organizations recommend standardized protocols for EV analysis and encourage integration into biomarker discovery pipelines. Future guideline updates in cardiology, nephrology, hepatology, and critical care medicine are likely to address the role of EV biomarkers in risk stratification, diagnosis, and monitoring of tissue injury, contingent on accumulating clinical validation data.

Conclusion

Extracellular vesicle cargo profiling represents a rapidly advancing frontier in the biomarker landscape of tissue injury and repair. The dynamic and context-specific nature of EV cargo offers unparalleled insights into underlying pathophysiological processes, with tangible clinical implications for early diagnosis, risk stratification, and therapeutic monitoring. Ongoing research, technological innovation, and standardization efforts are poised to accelerate the integration of EV biomarkers into routine clinical practice, ultimately improving outcomes for patients experiencing tissue injury across diverse organ systems.